Liminatus Pharma (LIMN) Non-Current Assets (2024 - 2026)

Liminatus Pharma (LIMN) posted Non-Current Assets of $11703.0 for Q1 2026, down 4.24% sequentially from $12221.0 in Q4 2025.

Liminatus Pharma (LIMN) Non-Current Assets (2024 - 2026) Analysis & Trends

Liminatus Pharma has reported Non-Current Assets for 3 years, with the latest figure at $11703.0 in Q1 2026.

Quarterly Non-Current Assets changed N/A year-over-year to $11703.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $11703.0 (changed N/A YoY) and the FY2025 annual result came in at $12221.0, down 90.39% from the prior year.
Non-Current Assets declined to $11703.0 in Q1 2026 per LIMN's latest filing, from $12221.0 in the prior quarter.
Over five years, Non-Current Assets peaked at $139039.0 in Q3 2025 and troughed at $11703.0 in Q1 2026.
A 3-year average of $83330.4 and a median of $126473.0 in 2025 frame the typical range for Non-Current Assets.
The widest YoY moves for Non-Current Assets: up 90.39% in 2025, down 90.39% in 2025.
Over 3 years, Non-Current Assets stood at $127216.0 in 2024, then plunged by 90.39% to $12221.0 in 2025, then slipped by 4.24% to $11703.0 in 2026.
According to Business Quant data, Non-Current Assets over the past three periods registered $11703.0, $12221.0, and $139039.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Non-Current Assets (Qtr)
1	Vertex Pharmaceuticals	139.59 Bn	131.73 Bn	2.84 Bn	14.88 Bn
2	Regeneron Pharmaceuticals	86.21 Bn	78.22 Bn	3.93 Bn	23.28 Bn
3	Argenx Se	65.65 Bn	60.47 Bn	1.37 Bn	1.96 Bn
4	Moderna	57.67 Bn	52.53 Bn	52.00 Mn	5.15 Bn
5	BeOne Medicines	42.10 Bn	37.00 Bn	1.53 Bn	1.96 Bn
6	Alnylam Pharmaceuticals	31.62 Bn	28.31 Bn	992.69 Mn	938.60 Mn
7	BioNTech SE	27.90 Bn	9.51 Bn	668.28 Mn	6.80 Bn
8	Insmed	27.51 Bn	26.35 Bn	358.27 Mn	468.65 Mn
9	Royalty Pharma	27.29 Bn	26.45 Bn	-	18.06 Bn
10	Liminatus Pharma	265.71 Mn	265.71 Mn	-	11,235.00

Download Data